DIAN Target Validation Symposium Agenda

The first DIAN Target Validation Symposium took place on May 25-26, 2023 in Washington, DC, USA.  Recorded presentations are available via hotlinks below but are password protected.  Please send request for passwords to zangela@wustl.edu.

Welcome/Opening Remarks: May 25

Dr. Randall Bateman, MD- Washington University School of Medicine, St. Louis, Mo


Primers on Target Validation: How we validate and factors that influence robustness- 8:45am

Moderator: Dr. Todd Golde, MD, PhD


Dr. Eric Karran, PhD– Vice President, Distinguished Research Fellow, Neuroscience and Ophthalmology Discovery Research at AbbVie

Presentation: Clinical Translation of Preclinical Targets by Dr. Geoffrey A. Kerchner, MD, PhD– Vice President and Global Head of Early Development in Neuroscience and Rare Disease at F. Hoffman- La Roche, Ltd

Panelist: Dr. Jaren Landen, PhD; Dr. Eric Karran, PhD, Dr. Geoffrey Kerchner, MD, PhD

Known Amyloid Target Validation- 10:30am

Moderator: Dr. Tammie Benzinger, MD, PhD


Dr. Lucia Chavez-Gutierrez, PhD– VIB-KU Leuven Center for Brain and Disease Research,  Leuven, Belgium

Dr. Jasmeer Chhawtal, MD, PhD– Harvard Medical School, Boston, MA

Panelist: Randall J. Bateman, MD; Dr. Colin Masters, MD; Dr. Lucia Chavez-Gutierrez, PhD; Dr. Jasmeer Chhawtal, MD, PhD

Known Tau Target Validation- 1:00pm

Moderator: Dr. Eric McDade, DO


Presentation: Tau Species in DIAN by Dr. Nicolas Barthelemy, PhD– Washington University School of Medicine, St. Louis, MO

Presentation: Biomarkers for Tau Target Validation by Dr. Oskar Hansson, PhD– Lund University, Lund, Sweden

Panelist: Dr. Judith Steen, PhD; Dr. Jeff Dage, PhD; Dr. Nicolas Barthelemy, PhD; Dr. Oskar Hansson, PhD

Potential Omics Target Validation-2:45pm

Moderator: Dr. Allan Levey, MD, PhD


Presentation: Proteomics in LOAD & ADAD by Dr. Erik Johnson, MD, PhD– Emory University, Atlanta, Georgia

Presentation: MS4A4A Modifiers AD Risk by Regulating Microglia States by Dr. Celeste Karch, PhD– Washington University School of Medicine, St. Louis, Mo

Panelists: Dr. Li-Huei Tsai, PhD; Dr. Laura Ibanez, PhD; Dr. Erik Johnson, MD, PhD; Dr. Celeste Karch, PhD

Closing Remarks: May 25

Dr. Randall Bateman, MD- Washington University School of Medicine, St. Louis, MO


Opening Remarks: May 26

 Dr. Randall Bateman, MD- Washington University School of Medicine, St. Louis, Mo


Biomarkers for non-Amyloid/non Tau Target Validation- 8:45am

Moderator: Dr. Johannes Levin, MD


Presentation: Outcome Measures in AD Trials-Astrocytes by Dr. Charlotte Teunissen, PhD – Amsterdam University Medical Centers, Amsterdam, Netherlands

Presentation: Biomarkers for non-Amyloid/non-Tau Target Validation: soluble TREM2 by Dr. Marc Suárez-Calvet, MD, PhD–  BarcelonaBeta Brain Research Center (BBRC), Barcelona, Spain

Panelists: Dr. Naresha Saligrama, PhD; Dr. Pedro Rosa-Neto, MD, PhD; Dr. Charlotte Teunissen, PhD; Dr. Marc Suarez- Calvet, MD, PhD

Clinical/Cognitive Validation of Targets- 10:30am

Moderator: Dr. Jorge Llibre-Guerra, MD, MS


Presentation: Development & Validation of Clinically Meaningful Target in AD Trials by Dr. Lynn Kramer, MD, FAAN– Chief Clinical Officer, Alzheimer’s Disease & Brain Health at Eisai

Presentation: Validating Clinical Outcomes-Prevention & Minimal Symptomatic Stage by Dr. Paul Maruff, PhD– Chief Innovation Officer at Cogstate, Ltd and Professor at the Alzheimer’s Disease Research Group, Florey Institute for Neuroscience at the University of Melbourne, Australia

Panelists: Dr. Jason Hassenstab, PhD; Dr. Eric McDade, DO; Dr. Kathy Welsh-Bohmer, PhD; Dr. Lynn Kramer, MD; Dr. Paul Maruff, PhD


Moderator: Dr. Alison Goate, DPhil


Presentation: Untangling the Role of Rare Genetic Variants in Protecting Against Alzheimer’s Disease: From Biomarker to Novel Therapeutic Targets by Dr. Yakeel T. Quiroz, PhD– Harvard Medical School, Boston, MA

Panelists: Dr. Jorge Llibre-Guerra, MD, MS; Dr. Alison Goate, DPhil; Dr. Yakeel Quiroz, PhD

Disease Modification- 1:45pm

Moderator: Dr. Randall J. Bateman, MD


Presentation: DIAN Target Validation Symposium: Dominantly Inherited AD compared to sporadic AD for Disease Modification by Dr. Randall Bateman, MD– Washington University School of Medicine, St, Louis Mo

Presentation: How to Clinically Demonstrate Disease Modification & Target Validation by Dr. Alireza Atri, MD, PhD– Director at Banner Sun Health Research Institute, Sun City , AZ

Panelist: Dr. Allan Levey, MD, PhD; Dr. Michael Irizzary, MD, MPH; Dr. Randall Bateman, MD; Dr. Alireza Atri, MD, PhD

TU Pharma Consortium – 3:15pm

Dr. Randall Bateman, MD- Washington University School of Medicine, St. Louis, MO

Closing Remarks– May 26

Dr. Randall Bateman, MD- Washington University School of Medicine, St. Louis, MO